Gossamer and Chiesi Work Together to Create a Medication Addressing Respiratory Conditions

The purpose of seralutinib by Gossamer is to medicate pulmonary arterial hypertension in addition to additional indicators.

To create and market seralutinib for the treatment of respiratory disorders, Chiesi Group and Gossamer Bio have announced a worldwide cooperation and licence deal.

PAH is an uncommon progressive disorder which leads to elevated blood pressure in the arteries that supply the respiratory tract, with up to 50,000 individuals in the US estimated to be affected. In the US, PH-ILD is thought to impact as many as 100,000 people.

Gossamer will lead commercialization and publish revenue for PAH and PH-ILD, while Chiesi will drive commercialization in further areas. Both businesses will equally split commercial revenues and expenses, providing 50% of commercial work in the US.

Co-founder, chairman and chief executive officer of Gossamer stated: “This collaboration enables seralutinib to move directly into a phase 3 trial in PH-ILD, an indication with a paucity of available treatments and a disease which we believe seralutinib is specifically designed to address.”

Group chief executive officer of Chiesi commented: “Seralutinib is a potential paradigm shifting therapy in PAH and PH-ILD and we… [are] excited to partner with Gossamer to develop and bring this therapy to patients worldwide.”